Most Chinese biological manufacturers describe themselves by the size of their portfolio. This one has a single product, and that is worth understanding before you read anything else: a company making one vaccine for years is not an unambitious company, it is a company whose process validation has been focused on one thing.
The entity, in verifiable terms
- Registered entity
- Guangzhou Baiyunshan Biological Products Co., Ltd. (广州白云山生物制品股份有限公司)
- Group
- Guangzhou Pharmaceutical Holdings (GPHL), a Fortune Global 500 group. The subsidiary is not separately listed — for company-level financials you look to the group, for site-level licensing you look to this entity
- Headquarters
- Guangzhou, Guangdong Province
- Distinction
- The only human-vaccine industrialisation enterprise based in Guangzhou
- Portfolio
- One product: freeze-dried rabies vaccine (Vero cell)
- Formulation
- Free of gelatin, antibiotics and preservatives — stated on the product's own specification, not inferred from marketing material
- Overseas registration
- Not yet initiated. Read the section below before assuming this is a shortcoming
Why the cell substrate matters more than the brand
There are two rabies vaccine substrates in common Chinese production: Vero cells and hamster kidney cells. The other manufacturer we carry, Bohui, uses hamster kidney cells. Both products are licensed by NMPA and both are legitimate; they are not interchangeable in a regulatory dossier.
If your market already has an approved rabies vaccine on file, the substrate named in that approval constrains what you can register next. Switching substrate is a new registration, not a variation. Decide this before you negotiate price.
The formulation detail — no gelatin, no antibiotics, no preservatives — is the kind of fact that looks like marketing until a pharmacist asks about it. Excipient lists are checked against local monographs during registration, and fewer excipients means fewer lines to defend.
The registration status, stated plainly
Overseas registration for this vaccine has not been initiated. That is not a defect in the product; it is a statement about paperwork that does not exist yet. What it means commercially:
- If your market requires a foreign registration before import, you are looking at a from-zero filing — typically 18–36 months, and the cost sits with whoever wants the territory.
- If your market permits import under an existing emergency or tender pathway, the timeline collapses and the product becomes interesting immediately.
- If you already hold a rabies vaccine registration from a different manufacturer, this product is a supply-diversification option rather than a drop-in replacement.
We treat this product as a joint-development territory rather than a catalogue item, which is why it appears on Open territories and why we would rather discuss your regulatory pathway than quote a price first.
What we supply from Baiyunshan
See all seventeen products across three manufacturers →
How to verify the entity yourself
- The product licence. The NMPA approval number on the product page is the one to check; this guide shows how the number decomposes and where to look it up.
- Batch release. Vaccines, like plasma products, cannot be released by the manufacturer alone. What the release certificate covers.
- The group. GPHL is a listed group; group filings will confirm the subsidiary exists and what it does, even though the subsidiary does not file separately.
What this page does not claim
We are an authorised export partner, not the manufacturer. Nothing here asserts efficacy or safety, and nothing is directed at patients. Availability and lead time are subject to the manufacturer's confirmation — and for this product, so is the question of whether an export pathway exists for your market at all.